CD134 plus CD137 dual costimulation induces eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation

Journal of Immunology

Volumn 187, Issue 7, 2011, Pages 3555-3564

  Qui, Harry Z ^a   Hagymasi, Adam T ^a   Bandyopadhyay, Suman ^a   St Rose, Marie Clare ^a   Ramanarasimhaiah, Raghunath ^a   Ménoret, Antoine ^a   Mittler, Robert S ^b   Gordon, Scott M ^c,d   Reiner, Steven L ^c,d   Vella, Anthony T ^a   Adler, Adam J ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; EOMESODERMIN; GRANZYME B; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DEGRANULATION; ENZYME INDUCTION; LYMPHOCYTE DIFFERENTIATION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD137; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL SEPARATION; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RECEPTORS, OX40; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS; TH1 CELLS;

EID: 80053502126     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101244     Document Type: Article

References (72)

1. Murphy, K. M., and S. L. Reiner. 2002. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2: 933-944. (Pubitemid 37323214)
2. Zhou, L., M. M. Chong, and D. R. Littman. 2009. Plasticity of CD4+ T cell lineage differentiation. Immunity 30: 646-655.
3. Glimcher, L. H., M. J. Townsend, B. M. Sullivan, and G. M. Lord. 2004. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4: 900-911. (Pubitemid 39490765)
4. Misko, I. S., J. H. Pope, R. Hütter, T. D. Soszynski, and R. G. Kane. 1984. HLADR- antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int. J. Cancer 33: 239-243. (Pubitemid 14184413)
5. Williams, N. S., and V. H. Engelhard. 1996. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J. Immunol. 156: 153-159. (Pubitemid 26006958)
6. Appay, V., J. J. Zaunders, L. Papagno, J. Sutton, A. Jaramillo, A. Waters, P. Easterbrook, P. Grey, D. Smith, A. J. McMichael, et al. 2002. Characterization of CD4(+) CTLs ex vivo. J. Immunol. 168: 5954-5958.
7. Jellison, E. R., S. K. Kim, and R. M. Welsh. 2005. Cutting edge: MHC class IIrestricted killing in vivo during viral infection. J. Immunol. 174: 614-618. (Pubitemid 40094252)
8. Topalian, S. L., L. Rivoltini, M. Mancini, N. R. Markus, P. F. Robbins, Y. Kawakami, and S. A. Rosenberg. 1994. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91: 9461-9465. (Pubitemid 24297934)
9. Ferrone, S., and F. M. Marincola. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16: 487-494.
10. Xie, Y., A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane, E. K. Kwon, P. Muranski, N. P. Restifo, and P. A. Antony. 2010. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207: 651-667.
11. Quezada, S. A., T. R. Simpson, K. S. Peggs, T. Merghoub, J. Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P. A. Antony, et al. 2010. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207: 637-650.
12. Verdeil, G., D. Puthier, C. Nguyen, A. M. Schmitt-Verhulst, and N. Auphan-Anezin. 2006. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J. Immunol. 176: 4834-4842.
13. Redmond, W. L., M. J. Gough, B. Charbonneau, T. L. Ratliff, and A. D. Weinberg. 2007. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J. Immunol. 179: 7244-7253.
14. Pipkin, M. E., J. A. Sacks, F. Cruz-Guilloty, M. G. Lichtenheld, M. J. Bevan, and A. Rao. 2010. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32: 79-90.
15. Pearce, E. L., A. C. Mullen, G. A. Martins, C. M. Krawczyk, A. S. Hutchins, V. P. Zediak, M. Banica, C. B. DiCioccio, D. A. Gross, C. A. Mao, et al. 2003. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302: 1041-1043. (Pubitemid 37386196)
16. Intlekofer, A. M., N. Takemoto, E. J. Wherry, S. A. Longworth, J. T. Northrup, V. R. Palanivel, A. C. Mullen, C. R. Gasink, S. M. Kaech, J. D. Miller, et al. 2005. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6: 1236-1244. (Pubitemid 43045635)
17. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3: 609-620. (Pubitemid 37328664)
18. Watts, T. H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68. (Pubitemid 40563164)
19. Lee, S. J., L. Myers, G. Muralimohan, J. Dai, Y. Qiao, Z. Li, R. S. Mittler, and A. T. Vella. 2004. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J. Immunol. 173: 3002-3012. (Pubitemid 39142005)
20. Lee, S. J., R. J. Rossi, S. K. Lee, M. Croft, B. S. Kwon, R. S. Mittler, and A. T. Vella. 2007. CD134 costimulation couples the CD137 pathway to induce production of supereffector CD8 T cells that become IL-7 dependent. J. Immunol. 179: 2203-2214.
21. Cuadros, C., A. L. Dominguez, P. L. Lollini, M. Croft, R. S. Mittler, P. Borgström, and J. Lustgarten. 2005. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int. J. Cancer 116: 934-943. (Pubitemid 41209201)
22. Gray, J. C., R. R. French, S. James, A. Al-Shamkhani, P. W. Johnson, and M. J. Glennie. 2008. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur. J. Immunol. 38: 2499-2511.
23. Lathrop, S. K., C. A. Huddleston, P. A. Dullforce, M. J. Montfort, A. D. Weinberg, and D. C. Parker. 2004. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J. Immunol. 172: 6735-6743. (Pubitemid 38669110)
24. Bandyopadhyay, S., M. Long, H. Z. Qui, A. T. Hagymasi, A. M. Slaiby, M. A. Mihalyo, H. L. Aguila, R. S. Mittler, A. T. Vella, and A. J. Adler. 2008. Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation. J. Immunol. 181: 7728-7737.
25. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669.
26. Tamada, K., and L. Chen. 2006. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol. Immunother. 55: 355-362. (Pubitemid 43076887)
27. Redmond, W. L., and A. D. Weinberg. 2007. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit. Rev. Immunol. 27: 415-436.
28. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. Von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180: 25-34. (Pubitemid 24181052)
29. Adler, A. J., C. T. Huang, G. S. Yochum, D. W. Marsh, and D. M. Pardoll. 2000. In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J. Immunol. 164: 649-655. (Pubitemid 30043684)
30. Higgins, A. D., M. A. Mihalyo, P. W. McGary, and A. J. Adler. 2002. CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement. J. Immunol. 168: 5573-5581. (Pubitemid 34556137)
31. Schorle, H., T. Holtschke, T. Hünig, A. Schimpl, and I. Horak. 1991. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352: 621-624. (Pubitemid 21912393)
32. Szabo, S. J., B. M. Sullivan, C. Stemmann, A. R. Satoskar, B. P. Sleckman, and L. H. Glimcher. 2002. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 295: 338-342. (Pubitemid 34074366)
33. Intlekofer, A. M., A. Banerjee, N. Takemoto, S. M. Gordon, C. S. Dejong, H. Shin, C. A. Hunter, E. J. Wherry, T. Lindsten, and S. L. Reiner. 2008. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 321: 408-411. (Pubitemid 352029977)
34. Babu, S., L. D. Shultz, T. R. Klei, and T. V. Rajan. 1999. Immunity in experimental murine filariasis: roles of T and B cells revisited. Infect. Immun. 67: 3166-3167. (Pubitemid 29244747)
35. Long, M., A. M. Slaiby, A. T. Hagymasi, M. A. Mihalyo, A. C. Lichtler, S. L. Reiner, and A. J. Adler. 2006. T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression. J. Immunol. 176: 1036-1045. (Pubitemid 43099704)
36. Long, M., and A. J. Adler. 2006. Cutting edge: paracrine, but not autocrine, IL-2 signaling is sustained during early antiviral CD4 T cell response. J. Immunol. 177: 4257-4261. (Pubitemid 44469751)
37. Bandyopadhyay, S., H. Z. Qui, and A. J. Adler. 2009. In vitro and in vivo differentiated effector CD8 T cells display divergent histone acetylation patterns within the Ifng locus. Immunol. Lett. 122: 214-218.
38. Glimcher, L. H., K. J. Kim, I. Green, and W. E. Paul. 1982. Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J. Exp. Med. 155: 445-459. (Pubitemid 12171290)
39. Heusel, J. W., R. L. Wesselschmidt, S. Shresta, J. H. Russell, and T. J. Ley. 1994. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76: 977-987. (Pubitemid 24106379)
40. Pipkin, M. E., and J. Lieberman. 2007. Delivering the kiss of death: progress on understanding how perforin works. Curr. Opin. Immunol. 19: 301-308. (Pubitemid 46687016)
41. Araki, Y., M. Fann, R. Wersto, and N. P. Weng. 2008. Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). J. Immunol. 180: 8102-8108.
42. Betts, M. R., J. M. Brenchley, D. A. Price, S. C. De Rosa, D. C. Douek, M. Roederer, and R. A. Koup. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281: 65-78. (Pubitemid 37324571)
43. Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. Science 248: 705-711.
44. Moon, J. J., H. H. Chu, M. Pepper, S. J. McSorley, S. C. Jameson, R. M. Kedl, and M. K. Jenkins. 2007. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27: 203-213. (Pubitemid 47284919)
45. Moon, J. J., H. H. Chu, J. Hataye, A. J. Pagán, M. Pepper, J. B. McLachlan, T. Zell, and M. K. Jenkins. 2009. Tracking epitope-specific T cells. Nat. Protoc. 4: 565-581.
46. Kaleeba, J. A., H. Offner, A. A. Vandenbark, A. Lublinski, and A. D. Weinberg. 1998. The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells. Int. Immunol. 10: 453-461. (Pubitemid 28182102)
47. Janas, M. L., P. Groves, N. Kienzle, and A. Kelso. 2005. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J. Immunol. 175: 8003-8010. (Pubitemid 41798362)
48. Brown, D. M., C. Kamperschroer, A. M. Dilzer, D. M. Roberts, and S. L. Swain. 2009. IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell. Immunol. 257: 69-79.
49. Bream, J. H., D. L. Hodge, R. Gonsky, R. Spolski, W. J. Leonard, S. Krebs, S. Targan, A. Morinobu, J. J. O'Shea, and H. A. Young. 2004. A distal region in the interferon-gamma gene is a site of epigenetic remodeling and transcriptional regulation by interleukin-2. J. Biol. Chem. 279: 41249-41257. (Pubitemid 39287727)
50. Williams, C. A., S. E. Murray, A. D. Weinberg, and D. C. Parker. 2007. OX40- mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet. J. Immunol. 178: 7694-7702. (Pubitemid 46898040)
51. Vu, M. D., X. Xiao, W. Gao, N. Degauque, M. Chen, A. Kroemer, N. Killeen, N. Ishii, and X. Chang Li. 2007. OX40 costimulation turns off Foxp3+ Tregs. Blood 110: 2501-2510. (Pubitemid 47523172)
52. So, T., and M. Croft. 2007. Cutting edge: OX40 inhibits TGF-beta- and antigendriven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J. Immunol. 179: 1427-1430.
53. Malek, T. R., A. Yu, V. Vincek, P. Scibelli, and L. Kong. 2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice: implications for the nonredundant function of IL-2. Immunity 17: 167-178. (Pubitemid 35245959)
54. Melero, I., J. V. Johnston, W. W. Shufford, R. S. Mittler, and L. Chen. 1998. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190: 167-172. (Pubitemid 29011104)
55. Karulf, M., A. Kelly, A. D. Weinberg, and J. A. Gold. 2010. OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J. Immunol. 185: 4856-4862.
56. Lee, S. W., Y. Park, A. Song, H. Cheroutre, B. S. Kwon, and M. Croft. 2006. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J. Immunol. 177: 4464-4472. (Pubitemid 44469776)
57. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183. (Pubitemid 28124932)
58. Robertson, K. A., E. J. Usherwood, and A. A. Nash. 2001. Regression of a murine gammaherpesvirus 68-positive B-cell lymphoma mediated by CD4 T lymphocytes. J. Virol. 75: 3480-3482. (Pubitemid 32225912)
59. Romerdahl, C. A., and M. L. Kripke. 1988. Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. Cancer Res. 48: 2325-2328.
60. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368. (Pubitemid 29028508)
61. Surman, D. R., M. E. Dudley, W. W. Overwijk, and N. P. Restifo. 2000. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J. Immunol. 164: 562-565. (Pubitemid 30043673)
62. Croft, M. 2010. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28: 57-78.
63. Futagawa, T., H. Akiba, T. Kodama, K. Takeda, Y. Hosoda, H. Yagita, and K. Okumura. 2002. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14: 275-286. (Pubitemid 34213639)
64. Pauly, S., K. Broll, M. Wittmann, G. Giegerich, and H. Schwarz. 2002. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J. Leukoc. Biol. 72: 35-42.
65. Spörri, R., and C. Reis e Sousa. 2003. Newly activated T cells promote maturation of bystander dendritic cells but not IL-12 production. J. Immunol. 171: 6406-6413. (Pubitemid 37532068)
66. Gondek, D. C., L. F. Lu, S. A. Quezada, S. Sakaguchi, and R. J. Noelle. 2005. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174: 1783-1786. (Pubitemid 40223916)
67. Cao, X., S. F. Cai, T. A. Fehniger, J. Song, L. I. Collins, D. R. Piwnica-Worms, and T. J. Ley. 2007. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27: 635-646. (Pubitemid 47628832)
68. Maeurer, M. J., S. M. Gollin, D. Martin, W. Swaney, J. Bryant, C. Castelli, P. Robbins, G. Parmiani, W. J. Storkus, and M. T. Lotze. 1996. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 98: 1633-1641. (Pubitemid 26327874)
69. Jäger, E., M. Ringhoffer, M. Altmannsberger, M. Arand, J. Karbach, D. Jäger, F. Oesch, and A. Knuth. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71: 142-147. (Pubitemid 27252981)
70. Yee, C., J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche, E. Celis, and P. D. Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.s (Pubitemid 35462767)
71. Zhou, G., Z. Lu, J. D. McCadden, H. I. Levitsky, and A. L. Marson. 2004. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 200: 1581-1592. (Pubitemid 40094182)
72. Spiotto, M. T., D. A. Rowley, and H. Schreiber. 2004. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10: 294-298. (Pubitemid 38667621)